Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

Boston Scientific Corporation $BSX Shares Acquired by DSM Capital ...

AI-generated analysis

πŸ“ˆ DSM Capital Partners LLC increased its position in Boston Scientific by 11,846.4% in Q1, adding 559,625 shares to a total holding of 564,349 shares valued at $35.4 million.

πŸ“Š The company reported Q1 revenue of $5.20 billion, an 11.6% increase year-over-year, beating analyst estimates of $5.19 billion.

πŸ’° Boston Scientific posted EPS of $0.80 for the quarter, exceeding the consensus estimate of $0.79 by $0.01.

πŸ”„ The Board authorized a new share repurchase program allowing the company to buy back up to $5.00 billion in shares.

πŸ“‰ Analyst Citigroup lowered its price target from $87.00 to $70.00 while maintaining a 'buy' rating on the stock.

πŸ‘₯ Corporate insiders acquired 9,800 shares worth $554,012 over the last quarter, with director David C. Habiger increasing his stake by 19.35%.

πŸ“… The company set Q2 2026 EPS guidance between $0.820 and $0.840, and full-year 2026 EPS guidance between $3.340 and $3.410.

πŸ›οΈ Institutional investors own 89.07% of the company's outstanding shares, indicating strong institutional confidence.

Bullish Signals
  • DSM Capital Partners LLC executed a massive position increase of 11,846.4%, adding over half a million shares to its portfolio.
  • The company beat quarterly revenue expectations with $5.20 billion in sales, up 11.6% from the prior year.
  • Boston Scientific exceeded earnings estimates with $0.80 EPS compared to the consensus of $0.79.
  • Management initiated a substantial $5.00 billion share buyback program, authorizing the repurchase of up to 6.4% of shares.
  • Corporate insiders collectively purchased nearly $554,000 worth of stock in the last quarter, signaling internal confidence.
Risk Factors
  • Analyst Citigroup reduced its price target from $87.00 to $70.00, reflecting a more conservative valuation outlook.
  • Wall Street Zen and Daiwa Securities Group downgraded their ratings from 'buy' or 'strong-buy' to 'hold', indicating some caution.
Full Analysis
DSM Capital Partners LLC significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 11,846.4% in the first quarter, purchasing an additional 559,625 shares to hold a total of 564,349 shares valued at $35.4 million. Other institutional investors also adjusted their positions, with Ieq Capital LLC increasing its stake by 97.0% and Main Street Financial Solutions growing holdings by 35.3%. Corporate insiders, including directors Cheryl Pegus and David C. Habiger, collectively acquired 9,800 shares worth $554,012 in the last quarter, while institutional ownership remains high at 89.07%. Financially, Boston Scientific reported strong quarterly results with revenue of $5.20 billion, beating analyst expectations of $5.19 billion and representing an 11.6% year-over-year increase. The company posted earnings per share (EPS) of $0.80, surpassing the consensus estimate of $0.79, alongside a return on equity of 19.17% and a net margin of 17.29%. Management has set guidance for Q2 2026 EPS between $0.820 and $0.840, and full-year 2026 EPS between $3.340 and $3.410. In a move signaling confidence in its stock value, Boston Scientific's Board of Directors authorized a new share buyback plan on May 18th to repurchase up to $5.00 billion in shares, which could account for approximately 6.4% of the outstanding float. Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and a price target of $81.32, though some firms like Citigroup and Canaccord Genuity recently lowered their price targets to $70.00 while maintaining buy ratings.